Pfizer to buy Canadian ‘blockbuster’ cancer drug developer Trillium Therapeutics in $2.26-billion deal

Ontario Industry Updates
Written By Viktoriya Shabat
Asset-4-1.png

Pharma giant Pfizer Inc. recently announced it would buy Trillium Therapeutics Inc. in a deal valuing the Mississauga blood cancer drug developer at US$2.26-billion. Pfizer invested US$25-million last year in Trillium, picking up 2.3 million shares. It’s the second-largest deal for a Canadian biotech company on record, after Shire Pharmaceuticals Group PLC’s $5.9-billion CAD purchase of AIDS drug developer BioChem Pharma Inc. 20 years ago.

Viktoriya Shabat
Previous

OBIO Investment Summit Participant, MedStack, Raises $3.1M USD in an Oversubscribed Pre-Series A Round to Fuel its Growth Momentum
Next

OBIO’s H2BB™ Workforce Development Program Accredited by the University of Toronto School of Continuing Studies